Detalhe da pesquisa
1.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
Blood
; 139(7): 1066-1079, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699595
2.
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.
Blood
; 137(1): 61-74, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640012
3.
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses.
Oncogene
; 42(21): 1751-1762, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031341
4.
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Cancer Lett
; 568: 216284, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356470
5.
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.
Sci Rep
; 12(1): 10616, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35739276
6.
Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment.
Cell Rep
; 40(7): 111201, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977482
7.
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
J Immunother Cancer
; 6(1): 65, 2018 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29970158
8.
Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.
Leuk Lymphoma
; 60(10): 2558-2562, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30845856